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A major challenge in unrelated hematopoietic stem cell transplantation (HSCT) is the prediction of permissive
HLA mismatches, ie, those associated with lower clinical risks compared to their nonpermissive counterparts.
For HLA-DPB1, a clinically prognostic model has been shown to be matching for T cell epitope (TCE) groups
assigned by cross reactivity of T cells alloreactive to HLA-DPB1*09:01; however, the molecular basis of this
observation is not fully understood. Here, we have mutated amino acids (aa) in 10 positions of HLA-
DPB1*09:01 to other naturally occurring variants, expressed them by lentiviral vectors in B cell lines, and
quantitatively measured allorecognition by 17 CD4þ T cell effectors from 6 unrelated individuals. A signiﬁcant
impact on the median alloresponse was observed for peptide contact positions 9, 11, 35, 55, 69, 76, and 84, but
not for positions 8, 56, and 57 pointing away from the groove. A score for the “functional distance” (FD) from
HLA-DPB1*09:01 was deﬁned as the sum of the median impact of polymorphic aa in a given HLA-DPB1 allele
on T cell alloreactivity. Established TCE group assignment of 23 alleles correlated with FD scores of 0.5, 0.6 to
1.9 and 2 for TCE groups 1, 2, and 3, respectively. Based on this, prediction of TCE group assignment will be
possible for any given HLA-DPB1 allele, including currently 367 alleles encoding distinct proteins for which T
cell cross reactivity patterns are unknown. Experimental conﬁrmation of the in silico TCE group classiﬁcation
was successfully performed for 7 of 7 of these alleles. Our ﬁndings have practical implications for the
applicability of TCE group matching in unrelated HSCT and provide new insights into the molecular mech-
anisms underlying this model. The innovative concept of FD opens new potential avenues for risk prediction
in unrelated HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION disorders [1-6] or with nonmalignant disorders [7]. How-It is generally accepted that high-resolution matching for
8/8 HLA-A, B, C, and DRB1 alleles between unrelated donors
(UD) and recipients signiﬁcantly improves the clinical
outcome of hematopoietic stem cell transplantation (HSCT),
at least in patients with early stage onco-hematologicdgments on page 240.
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14.10.017
ty for Blood and Marrow Transplantation.ever, everyday transplantation practice has to face the
frequent presence of 1 or more mismatches in the majority
of transplantations. This is due to the difﬁculties of ﬁnding
an 8/8-matched UD for 30% to 60% of patients, depending to
their ethnic origin [8,9], as well as the presence of HLA-
DPB1 mismatches in over 80% of unrelated HSCT resulting
from the weak linkage disequilibrium between HLA-DPB1
and the other class II loci [10]. However, evidence for the
existence of certain permissive mismatch combinations, ie,
mismatches associated with lower clinical risks compared
with their nonpermissive counterparts, is accumulating.
P. Crivello et al. / Biol Blood Marrow Transplant 21 (2015) 233e241234Attempts for identifying permissive mismatches include the
statistical analysis of the clinical risks associated with
certain HLA mismatches involving deﬁned amino acid (aa)
positions [11,12]. These data point to the presence of qual-
itative differences between individual polymorphisms in
the HLA molecule, possibly reﬂecting the relative impact of
aa variability on alloreactive T cells mediating the clinical
effects of histocompatibility barriers. In line with this
notion, our group developed and clinically validated a
functional algorithm for nonpermissive HLA-DPB1 T cell
epitope (TCE) mismatches [13-16]. This model is based on
the observation of reproducible cross reactivity patterns
displayed by T cells alloreactive to nominal HLA-
DPB1*09:01, towards 23 different HLA-DPB1 alleles stud-
ied to date. This led to the classiﬁcation of HLA-DPB1 alleles
into at least 3 different TCE groups based on their ability to
be recognized by all (TCE group 1; DPB1*09:01, 10:01, 17:01),
some (TCE group 2; DPB1*03:01, 14:01, 45:01, 86:01,
104:01), or none (TCE group 3; DPB1*01:01, 02:01, 02:02;
04:01, 04:02, 05:01, 06:01, 11:01, 13:01, 15:01, 16:01, 19:01,
20:01, 23:01, 46:01) of 7 different T cell clones studied
[16,17]. UD-recipient HLA-DPB1 mismatches were classiﬁed
as permissive or nonpermissive, according to whether they
involved alleles from the same or from different TCE groups,
respectively. Nonpermissive HLA-DPB1 TCE group mis-
matches were shown to be associated with signiﬁcantly
higher clinical risks after well-matched unrelated HSCT
compared with permissive mismatches. This was demon-
strated retrospectively in many, though not all, multicenter
retrospective studies [13,14,16,18-21], as well as in 2 recent
independent investigations involving over 5000 patients
each [15,22]. Based on this, an online Web tool for the
identiﬁcation of nonpermissive HLA-DPB1 TCE group mis-
matches in UD searches has been developed (www.ebi.a-
c.uk/ipd/imgt/hla/dpb.html) [23]. A practical constraint to
the clinical applicability of this Web tool is the limited
number of HLA-DPB1 alleles that have been functionally
assigned to TCE groups, ie, 23 of 390 (5.9%) alleles encoding
distinct proteins known to date (http://www.ebi.ac.uk/ipd/
imgt/hla/).
Here, we have sought to investigate the correlation
between TCE groups and aa sequence variability at individual
positions of HLA-DPB1 to determine the relationship
between functional and structural characteristics in a clini-
cally relevant model of permissive mismatches in unrelated
HSCT.Table 1
Site-Directed Mutants of HLA-DPB1*09:01
HvR Mutant
Name
Naturally
Occurring
HLA-DPB1*
8 9 11
- WT 09:01 V H L
A V8L - L - -
H9Y 88:01 - Y -
H9F - - F -
L11G - - - G
B F35Y - - - -
F35L - - - -
C D55A - - - -
E56A - - - -
D57E 10:01 - - -
D E69K 35:01 - - -
E V76M 17:01 - - -
F D84G - - - -
HvR indicates hypervariable regions.
The naturally occurring counterparts listed for individual mutants have identical aMATERIALS AND METHODS
Cells, Cell Lines, and HLA Typing
Peripheral blood mononuclear cells (PBMC) were obtained from healthy
blood or stem cell donors after written informed consent approved by the
San Raffaele Ethic Committee. B lymphoblastoid cell lines (BLCL), either
locally established or purchased from the European Collection of Animal Cell
cultures, are listed along with their respective HLA types in Table S1. High-
resolution molecular HLA-A, B, C, DRB1, DQB1, and DPB1 typing of locally
obtained PBMC or BLCL was performed by standard techniques under the
quality guidelines from the European Federation for Immunogenetics
(http://www.eﬁweb.eu).
Monoclonal Antibodies and Flow Cytometry
Monoclonal antibodies (mAbs) included antielow-afﬁnity nerve growth
factor receptor (DLNGFR)-Allophycocyanin (clone ME20.4) (Miltenyi Biotec,
Bergisch Gladbach, Germany), anti-CD4-PE-Cyanin7 (clone RPA-T4), anti-
CD137-Allophycocyanin (clone 4B4-1) (Becton Dickinson, Franklin Lakes,
NJ), anti-pan HLA-DP (clone B7/21) (Cancer Research Technology Limited,
London, UK), anti-HLA-DP-DEAV[84-87] (clone TL-3B6), anti-HLA-DR (clone
L243) (Biolegend, San Diego, CA), and anti-human IgG-FITC (Jackson
ImmunoResearch, Newmarket, UK). T cell receptor (TCR) variable beta chain
region (Vb) typing was performed using the IOTest Beta Mark TCR-Vb
Repertoire Kit (Beckman Coulter, Indianapolis, IN).
Flow cytometry data acquisition was performed on a FACS Canto II
(Becton Dickinson) using FACSDiva software (Becton Dickinson). Subsequent
data analysis was performed using FCS Express 4.0 software (De Novo
Software, Los Angeles, CA).
Site-directed Mutagenesis of HLA-DPB1*09:01 and Expression in Read-
out Cell Lines
Site-directed mutagenesis (SDM) of wild type (WT) HLA-DPB1*09:01,
PCR-ampliﬁed from cDNA extracted from local PBMC, was performed us-
ing the QuikChange II kit (Agilent Technologies, Santa Clara, CA), according
to manufacturer’s instructions, and conﬁrmed by Sanger sequencing.
WT and mutant HLA-DP expression by BLCL was driven by a bidirec-
tional lentiviral expression platform, as previously described [24,25],
inducing coordinate expression of transgenic HLA-DPB1 and the DLNGFR
reporter. After magnetic bead puriﬁcation for reporter gene expression, cell
surface expression levels of transgenic DLNGFR or HLA-DPB1 were quanti-
tatively assessed by ﬂow cytometric determination of Molecules of Equiv-
alent Soluble Fluorochrome [26] using SPHERO Rainbow Calibration
Particles (Spherotech, Lake Forest, IL) [25].
Isolation and Characterization of CD4þ T Cells Alloreactive to HLA-
DPB1*09:01
PBMC from responder-stimulator pairs matched for 9 to 10/10 of the
HLA-A, B, C, DRB1, and DQB1 alleles but mismatched for HLA-DPB1, were
used for the set-up of 1-way mixed lymphocyte reactions (MLR) as previ-
ously described [25]. PBMC were from a patient before transplantation or at
the time of HSCT allograft rejection [27] or from 5 different HLA-typed
healthy subjects. For complete HLA typing of the PBMC, see typing of the
respective BLCL in Table S1. After 2 rounds of stimulation, T cells were either
cloned by limiting dilution or left uncloned and maintained by repeated
restimulations, as described [25]. Allospeciﬁcity of T cell clones was estab-
lished by IFN-g ELISpot assays according to standard protocols [28,29] andAa Position
35 55 56 57 69 76 84
F D E D E V D
- - - - - - -
- - - - - - -
- - - - - - -
- - - - - - -
Y - - - - - -
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- - - E - - -
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- - - - - - G
a sequences in the peptide antigen-binding groove.
C D
B
A
Figure 1. Intra- and interindividual variability of sensitivity to single aa substitutions for allorecognition of HLA-DPB1*09:01 by CD4þ T cell clones. Allorecognition of
MGAR (black and hatched bars) or VAVY (grey bars) BLCL after lentiviral transduction with WT (DP9) or mutant HLA-DPB1*09:01 (Table 1), or with irrelevant control
HLA-DPB1 (CTR), by clonal alloreactive CD4þ T cells (Table S2). CTR was HLA-DPB1*01:01 for MGAR and HLA-DPB1*04:01 for VAVY. Shown is for all clones the
number of spots counted in IFN-g ELISpot assays in response to transduced BLCL (ﬁlled bars). For clones 4 and 6, the percentage of T cells expressing CD137 in
response to transduced BLCL is additionally shown on the right axis (hatched bars). (A) T cell clones from PBMC obtained from a patient at the time of HSCT allograft
rejection (clones 1 and 2), or before transplantation (clone 3). (B-D) T cell clones from PBMC obtained from 3 unrelated healthy responder-stimulator pairs. Results are
expressed as mean  SD of 3 to 5 (IFN-g ELISpot assays) and 2 (CD137 assays) independent experiments. Statistical comparisons between alloresponses to each
mutant versus WT DPB1*09:01 were performed by the unpaired 2-tailed t-Test (*P < .05, **P < .01, ***P < .001).
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tration of 1 mg/mL. Alloreactive TCR-Vb subfamilies in uncloned T cell cul-
tures were analyzed by ﬂow-cytometric CD137 upregulation assays as
described [25,30,31], using appropriately labeled anti-CD4 and anti-CD137
mAb in combination with mAb for different TCR-Vb subfamilies. A list of
alloreactive T cells used, along with their TCR-Vb subfamilies and their
allospeciﬁcity, is included as Table S2.
The relative response (RR) of CD4þ T cells to mutant versus WT HLA-
DPB1*09:01 was calculated as response[mutant]response[negative control]/
response[WT]response[negative control], where response was the number of
IFN-g dots in ELISpot assays or the percentage of CD4þ CD137þ positive T
cells per TCR-Vb family in CD137 upregulation assays.Statistical Analyses
Statistical comparisonswere performed using the unpaired t-test, with P
< .05 as threshold for signiﬁcance. All statistical analyses were performed
using the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA).RESULTS
SDM of HLA-DPB1*09:01 and Expression in Read-out
BLCL
HLA-DPB1 TCE groups used to identify clinically permis-
sive mismatches in unrelated HSCT have been deﬁned in our
previous studies on the basis of reproducible cross reactivity
patterns displayed by T cells nominally alloreactive to HLA-
DPB1*09:01 [16,17]. We therefore used HLA-DPB1*09:01 as
reference allele for SDM of polymorphic aa in the a2 domain
encoded by exon 2. A total of 10 polymorphic aa residues
within hypervariable regions A through F, located at position
8, 9, 11, 35, 55, 56, 57, 69, 76, and 84, were swapped into a
residue naturally encoded by other HLA-DPB1 alleles,
resulting in a total of 12 point mutants of HLA-DPB1*09:01
(Table 1). The 10 positions were selected based on their
AB
Figure 2. Intra-individual variability of sensitivity to single aa substitutions for allorecognition of HLA-DPB1*09:01 by different TCR-Vb subpopulations. Shown is the
percentage of CD4 þ T cells upregulating the activation marker CD137 in response to MGAR BLCL transduced with HLA-DPB1*01:01 (CTR), WT (DP9) or mutant HLA-
DPB1*09:01 (Table 1), in 6 and 4 TCR-Vb subpopulations present in 2 uncloned T cells obtained after 2 rounds of stimulation in MLR between the responder/
stimulator pairs OSR-6392/OSR-5048 (A) and OSR-7285/OSR-0648 (B) (Tables S1 and S2). The percentage of the relevant TCR-Vb subpopulation within the total of
CD4þ T cells is shown on top of each graph. CD137 upregulation assays were performed as described in Materials and Methods. Only TCR-Vb subpopulations present
at 0.5% and signiﬁcantly (P < .05) upregulating CD137 after stimulation with WT HLA-DPB1*09:01 compared to CTR were analyzed. Results are mean  SEM of 3
independent experiments. Statistical comparison between alloresponses to each mutant versus WT HLA-DPB1*09:01 were performed by the 2-tailed unpaired t-Test
(*P < .05, **P < .01, ***P < .001).
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suggested by HLA-DP homology modeling (data not shown)
and the available literature [32-36].
WT or mutant HLA-DPB1*09:01, or HLA-DPB1*01:01
or 04:01 as negative controls, were lentiviral transduced
into the read-out BLCL MGAR or VAVY, homozygousfor HLA-DPB1*04:01/DPA1*01:03 and HLA-DPB1*01:01/
DPA1*02:01, respectively. Transgene expression levels were
assessed by quantitative PCR for transgenic HLA-DPB1 and by
cell surface staining for the DLNGFR reporter and, in the case
of MGAR, for the HLA-DPB1 DEAV[84-87] epitope selectively
encoded by transgenic but not endogenous DPB1 for this
AB
Figure 3. Overall impact of individual aa substitutions on allorecognition
of HLA-DPB1*09:01 by an alloreactive CD4þ T cell panel. (A) Relative response
(RR) of 17 CD4 þ T cells (Table S2) to individual aa substitutions in
HLA-DPB1*09:01 (Table 1) compared to WT set as 1.0 (dotted line). Each aa
mutation is represented by a different symbol. RR values were calculated
according to the formula Response[mutant]Response[negative control]/Respon-
se[WT]Response[negative control]. Data were derived from those reported in
Figure 2 for T cell clones and in Figure 4 for TCR-Vb subpopulations. (B) FDaa
value of each aa mutation, calculated as [1- median RR] from panel A. FDaa
values are distributed from lowest (0.12) to highest (0.96) overall impact on
allorecognition of HLA-DPB1*09:01.
Figure 4. HvR variability of HLA-DPB1 alleles according to their functional TCE
group classiﬁcation and FDallele scores. Shown are 23 HLA-DPB1 alleles
previously classiﬁed into TCE groups according to T cell cross reactivity
patterns [16,17], along with their aa polymorphism at the 10 positions
subjected to SDM in the present study (Table 1). The FDallele score of each of
these alleles was calculated as the sum of the FDaa values of each mutation, as
reported in Figure 5B. Variants D55E, E69R, V76I, and D84V, naturally occur-
ring in HLA-DPB1*05:01, 19:01, 11:01, 13:0,1 and 15:01 respectively, are indi-
cated in bold because they were not analyzed in this study and were not
considered (FDaa value 0).
P. Crivello et al. / Biol Blood Marrow Transplant 21 (2015) 233e241 237BLCL. Compared with WT HLA-DPB1*09:01, these experi-
ments revealed no signiﬁcant differences in transgene
expression levels for any of the mutants except for F35Y and
D57E, which showed consistently lower cell surface expres-
sion levels compared with WT on MGAR but not on VAVY
BLCL (data not shown).
CD4þ T Cell Effectors Alloreactive to HLA-DPB1*09:01
A panel of 17 CD4þ T cell effectors alloreactive to HLA-
DPB1*09:01 or to 10:01, both from TCE group 1, was
obtained from 6 different individuals, including a patient at
the time of graft rejection after allogeneic HSCT [27], by
1-wayMLR as described inMaterials andMethods (Table S2).
The 17 effectors included 7 T cell clones obtained by limiting
dilution cloning and 10 different HLA-DP allospeciﬁc TCR-Vb
subpopulations from 2 CD4þ T cell lines. Allospeciﬁcity of the
T cell effectors was demonstrated by IFN-g ELISPOT and/or
CD137 upregulation assays against allogeneic stimulator
versus autologous responder BLCL, and for T cell clones by
mAb inhibition studies on stimulator BLCL (Table S2).
According to the HLA-DPa chain preference for allor-
ecognition of WT HLA-DPB1*09:01 displayed by the
different T cell effectors (data not shown), MGAR or VAVY
BLCL were chosen as read-outs for recognition of mutant
HLA-DPB1*09:01 in further studies.
Role of Individual aa Substitutions for Allorecognition of
HLA-DPB1*09:01
To study the impact of single aa substitutions on allor-
ecognition of HLA-DPB1*09:01, the ability of individual
alloreactive T cell effectors to recognize single aa mutants of
HLA-DPB1*09:01 was evaluated in comparison to WT. Seven
Tcell clones were analyzed by IFN-g ELISPOTand 2 of them in
parallel also by CD137 assays with superimposable results
(Figure 1). Marked intra- and interindividual variability of
sensitivity to different aa substitutions was found for the 7
clones, with none of them displaying identical patterns of
sensitivity. Similar results were obtained when the allores-
ponse to WT or mutant HLA-DPB1*09:01 was tracked for 10
TCR-Vb subpopulations in oligoclonal T cell lines using the
CD137 assay [30] (Figure 2).
On the basis of these data, an overall impact of individual
aa substitutions on allorecogntion of HLA-DPB1*09:01 could
be assessed as the median RR of all 17 T cells to mutant
compared with WT (Figure 3A). The highest functional
impact was observed for mutations L11G, E69K, and D84G,
each with a median RR of < 0.07, reﬂecting abrogation of
allorecognition by nearly all T cells studied, followed by H9Y
and F35Y with a median RR of 0.15 and 0.13, respectively. In
contrast, no signiﬁcant impact was observed for mutations
F35L, V8L, E56A, and D57E, with a median RR of 0.95 or >1.0,
reﬂecting similar or even better allorecognition of the
mutants compared to WT HLA-DPB1*09:01 by most of the T
cells studied (Figure 3A).
The Median Impact of aa Variability on T Cell
Alloreactivity Deﬁnes a Functional Distance between
HLA-DPB1 Alleles
To compare the relative impact of individual aa sub-
stitutions on allorecognition, each aa was assigned with a
numerical value termed FD from the corresponding residue
in WT HLA-DPB1*09:01, deﬁned as 1-median RR. According
to this deﬁnition, all aa present in WT HLA-DPB1*09:01 have
a FDaa value of 0, and FDaa values for individual mutations
AB
Figure 5. Comparative evaluation of HLA-DPB1 TCE group classiﬁcation by alloreactive T cell cross reacitivity patterns and by FDallele scores. Shown is the number
(mean of 3 to 5 independent experiments) of spots counted in IFN-g ELISpot assays in response to BLCL expressing different endogenous HLA-DPB1 alleles, by 7 T cell
clones from this study (Table S2). HLA-DPB1 alleles are shown in the order of rising FDallele scores. Note recognition by most, some or none of the T cell clones for
HLA-DPB1 alleles in TCE groups 1, 2, and 3, respectively. (A) Recognition of 7 of 23 HLA-DPB1 alleles previously assigned to TCE group 1, 2, or 3 on the basis of
alloreactive T cell cross reactivity patterns [16,17]. (B) Recognition of 7 of 367 HLA-DPB1 alleles newly assigned to TCE groups 1, 2, or 3 on the basis of their FDallele
scores.
P. Crivello et al. / Biol Blood Marrow Transplant 21 (2015) 233e241238range from 0 or below to a maximum of 1 with increasing
overall negative impact on T cell allorecognition (Figure 3B).
Because all mutations analyzed correspond to naturally
occurring variants, individual FDaa values could be used to
calculate an overall FDallele score of each HLA-DPB1 allele as
the sum of individual FDaa values. In this model, the FDallele
score of the reference WT HLA-DPB1*09:01 is 0, as all indi-
vidual FDaa values are 0. A list of FDallele scores for all 390
HLA-DPB1 alleles encoding different proteins known to date
is given in Table S3. The FDallele scores range from -0.16 for
HLA-DPB1*54:01 to 5.67 for HLA-DPB1*158:01. It should be
noted that aa polymorphisms different in position or type
from those studied here were not considered and assigned
with an FDaa value of 0, suggesting that some of the assigned
FDallele scores might be underestimated.
The Functional Distance from HLA-DPB1*09:01 is
Predictive of HLA-DPB1 TCE Groups
In our previous studies, 23 HLA-DPB1 alleles were
assigned to TCE groups 1, 2, and 3 on the basis of their cross
recognition by 5 of 5, 2 of 5, or 0 of 5 T cell clones from a
patient before or at the time of HSCT allograft rejection,
including clone numbers 1 through 3 from the present study
[16,17]. The FDallele scores of these 23 HLA-DPB1 alleles were
found to be predictive of their respective TCE group assign-
ment, with TCE groups 1, 2, and 3 falling into FDallele score
ranges of 0.5, 0.6 to 1.9, and 2, respectively (Figure 4). The
only 2 exceptions were HLA-DPB1*06:01 and 19:01, which
had been assigned to TCE group 3 because they were
recognized by 0 of 5 T cell clones studied [16] but displayed
FDallele scores of 1.41 and 1.43, respectively, compatible withTCE group 2. When these 2 alleles were reanalyzed using the
7 alloreactive T cell clones from this study, lack of recognition
by clone numbers 1 through 3 was conﬁrmed; however, both
alleles were recognized by at least 1 of the other clones,
compatible with their assignment toTCE group 2 (Figure 5A).
On the basis of their FDallele scores, TCE group assignment
was predicted also for those 367 HLA-DPB1 alleles encoding
distinct proteins that so far lacked a functional assignment
(Table 2). For 7 of these alleles, the predicted assignment was
functionally tested according to the ability of 7 alloreactive T
cell clones from this study to recognize BLCL endogenously
expressing the relevant alleles (Figure 5B). For all 7 alleles,
the predicted TCE group assignment was conﬁrmed, with 6
of 7, 2 to 3 of 7, and 0 of 7 T cell clones recognizing alleles
assigned by the relevant FDallele score to TCE group 1
(DPB1*54:01), TCE group 2 (DPB1*37:01, 35:01, 55:01), or
TCE group 3 (DPB1*52:01, 68:01, 73:01), respectively. On the
basis of these results, TCE group assignment by FDallele score
can be performed not only for all existing HLA-DPB1 alleles
but also for any potential new allele that will be reported in
the future.
DISCUSSION
In this study, we present the innovative concept of FD for
the prediction of permissive HLA-DPB1 mismatches in
unrelated HSCT. Taking the lead from our clinically validated
model for functional matching [13,15-17,21], we show that
HLA-DPB1 TCE groups reﬂect their FD fromHLA-DPB1*09:01,
deﬁned as the combined median impact of individual aa
polymorphism in the hypervariable HLA-DPb-chain on T cell
alloreactivity. This model takes into account both the
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P. Crivello et al. / Biol Blood Marrow Transplant 21 (2015) 233e241 239heterogeneity of the T cell alloresponse to HLA-DPB1,
demonstrated previously by others [37] and conﬁrmed in
this study, and qualitative differences between individual aa
substitutions in the antigen-binding groove. Interestingly, aa
residues with a signiﬁcant impact on the median allores-
ponse were those predicted to be able to make contact with
bound peptide (positions 9, 11, 35, 55, 69, 76, and 84),
whereas no such impact was observed for residues pointing
away from the groove (positions 8, 56, and 57). This is in line
with recent data indicating that HLA-C*03:03/03:04 is a
permissive mismatch combination, possibly due to a limited
impact of the single aa difference at position 91 of the HLA
class I heavy chain encoded by the 2 variants, on peptide
binding and alloreactivity [38].
There are several peculiar characteristics to the FD model
that deserve attention. First, we investigated the functional
impact of 1 aa at a time, calculating the FDallele scores as the
sum of individual impacts. The possibility that certain aa
polymorphisms may have antagonizing rather than additive
effects when present in combination cannot be ruled out.
Second, some of the less frequent polymorphisms in HLA-
DPB1, with regards to both position and type, were not
studied and their impact was neglected in our FDallele score
calculations, raising the possibility that these scores might be
underestimated for some of the alleles. Third, FDallele scores
were determined here in reference to HLA-DPB1*09:01, the
nominal alloantigen used to establish T cell cross reactivity
patterns. Further studies using other reference DPB1 alleles,
such as HLA-DPB1*03:01 or 04:01, frequent alleles from TCE
groups 2 and 3, respectively, as well as HLA-DPB1*02:01,
which we proposed to represent a yet distinct fourth TCE
group [13], are necessary to determine if the classiﬁcation
established here is linear or complex. Based on these con-
siderations, the FDallele score boundaries for the TCE groups
should not be regarded as rigid. However, our results are
compatible with an emerging picture that HLA-DPB1 TCE
groups, and in turn their respective FDallele scores, reﬂect
structural differences that are correlated with the strength of
the alloreactive T cell response. In fact, we and others have
shown that the median magnitude of the MLR response is
higher against mismatched HLA-DPB1 alleles from different
TCE groups, compared with the MLR response against mis-
matched HLA-DPB1 alleles from the same TCE group [39-41].
Although TCE groups 1 and 2 are characterized by relatively
narrow FDallele score ranges of 0.0 to 0.5 and 0.6 to 1.9,
respectively, TCE group 3 included a broader range of FDallele
scores from 2.0 to 5.5, raising the possibility of further
functional heterogeneity of HLA-DPB1 alleles from this
group. Interestingly, HLA-DPB1*02:01 and 02:02 have been
proposed to represent a distinct fourth TCE group that
maintained clinical relevance when analyzed in algorithms
of permissivemismatches [13,15]. These 2 alleles have FDallele
scores of 2.94 and 2.95, respectively, which might delineate
an intermediate FDallele score boundary within TCE group 3.
Accordingly, TCE group 4 might include not only HLA-
DPB1*02:01 and 02:02, as previously suggested, but also
other alleles with FDallele scores ranging, for instance, be-
tween 2.0 to 3.0, including, for instance HLA-DPB1*05:01,
11:01, 13:01, 16:01, and 20:01. Further experimental and
clinical studies are needed to verify this point.
The ability to predict TCE group assignment of any HLA-
DPB1 allele based on the relevant FDallele score is of prac-
tical relevance for UD searches, for which a free online Web
tool is available for use in clinical practice as well as for
research purposes [23]. Indeed, in a recent study of 80
P. Crivello et al. / Biol Blood Marrow Transplant 21 (2015) 233e241240UD-recipient pairs from a Dutch transplantation center, the
TCE model could not be applied in 2 pairs (2.5%) because of
the presence of an HLA-DPB1 allele with unknown classiﬁ-
cation [42]. It is possible that the frequency of HLA-DPB1
alleles with unknown classiﬁcation might be even higher
in patients of non-Caucasian origin. In silico prediction of TCE
assignment for all known and future HLA-DPB1 alleles on the
basis of the data from the present study will allow us to
constantly update the Web tool, thereby eliminating the
problem of nonclassiﬁed rare HLA-DPB1 alleles once and for
all. In view also of the rapidly growing number of reported
HLA-DPB1 alleles, which rose by 224 alleles since January
2014, only (IMGT/HLA database release 3.16.0 and 3.18.0),
this possibility is particularly appealing.
The FD model represents a step forward from historical
[43] and more recent [12] observations correlating clinical
risks after unrelated HSCT with the matching status for
deﬁned aa residues in HLA class I by providing a weighted aa
scoring system based on functional evidence. It is intriguing
to speculate that the aa residues found to be involved in
permissive HLA-A, B, C mismatches [12] might reﬂect the
FDallele scores of the relevant alleles. In more general terms, it
can be envisaged that the experimental approach pioneered
here of validating established TCE groups in HLA-DPB1 by
their FD could also be undertaken inversely, ie, FDallele scores
could be used to identify TCE groups that could subsequently
be evaluated for risk prediction in unrelated HSCT. This
would be useful for HLA loci other than DPB1, where T cell
cross reactivity patterns that were the basis of the original
TCE grouping are likely to be less well deﬁned due to more
complex patterns of aa polymorphism. Ultimately, this might
represent an innovative experimental platform for the
identiﬁcation of permissive mismatches in unrelated HSCT.ACKNOWLEDGMENTS
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